ImmuCell Corp Reports Q1 Preliminary Revenue Growth Above 25% Driven By Tri-Shield Sales

ImmuCell reported preliminary Q1 2026 sales up 28.4% year-over-year, driven by strong Tri-Shield product sales. The result signals improving product demand in the animal health biologics business and is modestly positive for near-term equity performance.

Analysis

ImmuCell reported preliminary Q1 2026 sales up 28.4% year-over-year, driven by strong Tri-Shield product sales. The result signals improving product demand in the animal health biologics business and is modestly positive for near-term equity performance.